Condensed Consolidated Income Statements (unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|
| Revenues: | ||||
| Total revenues | $ 29,473,949 | $ 26,449,819 | $ 87,081,953 | $ 73,573,933 |
| Cost of revenues: | ||||
| Total cost of revenues | 2,604,100 | 2,337,095 | 7,674,296 | 6,705,169 |
| Selling and marketing expenses | 4,301,017 | 3,539,287 | 13,169,079 | 10,666,500 |
| Depreciation and amortization | 2,349,206 | 1,779,924 | 6,893,529 | 4,578,450 |
| General and administrative expenses | 20,212,750 | 17,796,806 | 60,156,022 | 51,900,533 |
| Total selling, general and administrative expenses | 26,862,973 | 23,116,017 | 80,218,630 | 67,145,483 |
| Net loss on disposition or impairment | 904,923 | 264,391 | 1,114,738 | 360,140 |
| Income (loss) from operations | (898,047) | 732,316 | (1,925,711) | (636,859) |
| Other income (expense), net | (6,244) | (25,235) | 3,708,399 | (60,668) |
| Income (loss) before income tax (benefit) expense | (904,291) | 707,081 | 1,782,688 | (697,527) |
| Income tax (benefit) expense | (188,018) | (24,015) | 493,286 | (560,976) |
| Net (loss) income | $ (716,273) | $ 731,096 | $ 1,289,402 | $ (136,551) |
| Earnings per share: | ||||
| Basic earnings (loss) per share (in dollars per share) | $ (0.05) | $ 0.05 | $ 0.09 | $ (0.01) |
| Diluted earnings (loss) per share (in dollars per share) | $ (0.05) | $ 0.05 | $ 0.09 | $ (0.01) |
| Basic weighted average shares (in shares) | 14,790,663 | 14,512,856 | 14,666,222 | 14,474,323 |
| Diluted weighted average shares (in shares) | 15,015,953 | 14,829,629 | 14,931,474 | 15,119,264 |
| Revenues from company-owned or managed clinics | ||||
| Revenues: | ||||
| Total revenues | $ 17,882,303 | $ 15,836,327 | $ 52,813,098 | $ 42,936,298 |
| Royalty fees | ||||
| Revenues: | ||||
| Total revenues | 7,143,791 | 6,604,653 | 21,181,973 | 19,024,799 |
| Franchise fees/Franchise and regional development cost of revenues | ||||
| Revenues: | ||||
| Total revenues | 754,029 | 642,405 | 2,179,822 | 1,970,256 |
| Cost of revenues: | ||||
| Cost of revenues | 2,228,689 | 1,988,764 | 6,605,964 | 5,694,723 |
| Advertising fund revenue | ||||
| Revenues: | ||||
| Total revenues | 2,050,106 | 1,881,367 | 6,043,563 | 5,417,840 |
| Software fees/IT cost of revenues | ||||
| Revenues: | ||||
| Total revenues | 1,301,577 | 1,109,753 | 3,746,394 | 3,166,732 |
| Cost of revenues: | ||||
| Cost of revenues | 375,411 | 348,331 | 1,068,332 | 1,010,446 |
| Other revenues | ||||
| Revenues: | ||||
| Total revenues | $ 342,143 | $ 375,314 | $ 1,117,103 | $ 1,058,008 |
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|